期刊文献+

血清促红细胞生成素水平与急性心肌梗死患者梗死面积有关 被引量:1

Serum erythropoietin levels is associated with infarct size in patients with acute myocardial infarction
原文传递
导出
摘要 目的观察血清促红细胞生成素(EPO)水平与急性心肌梗死(AMI)直接经皮冠状动脉介入(PCI)治疗后梗死面积的关系。方法初次急性ST段抬高型心肌梗死86例,在发病12 h内成功地接受了PCI的患者测定血清EPO和肌酸肌酶(CK),并计算其CK累积释放量。以EPO中间值(19.6 U/L)分为高EPO组[(39±17)U/L]和低EPO组[(14±4)U/L],对两组CK累计释放量进行比较,并对CK累积释放量的可能影响因素做多元逐步回归分析。结果CK累积释放量在血清高EPO组明显低于低EPO组[(1 150±226)μkat/(L.h)vs(1 740±210)μkat/(L.h),P<0.05)]。多元逐步回归分析显示,血清EPO水平、PCI术后TIMI血流等级和梗死前心绞痛是CK累积释放量的独立预测因子。结论内源性EPO水平高者AMI成功地直接PCI术后梗死面积较少,两者呈负相关。 AIM To study the relation between serum erythropoietin (EPO) levels and the infarct size in patients with acute myocardial infarction (AMI) who had undergone successful primary percutaneous coronary intervention (PCI). METHODS We studied 86 patients with first ST-segment elevation MI who had received successful primary PCI whthin 12 h from the onset of MI. The serum EPO level and creatine kinase (CK) were measured and the cumulative CK release was calculated. We divided the 86 patients into two groups using the median value( 19.6 U/L) of the serum EPO levels. A stepwise multiple regression analysis was conducted to assess the possible determinants of cumulative CK release. RESULTS The cumulative CK release of the high EPO group was significantly lower than that of the low EPO group [ ( 1 150±226) μkat/( L·h) vs ( 1 740 ±210) μkat/( L·h), P 〈0. 05 ) ]. The stepwise multiple regression analysis revealed that the absolute serum EPO levels (U/L) , TIMI grads after PCI and preinfarction angina were independent predictors for the cumulative CK release. CONCLUSION The infarct size of the high endogenous EPO level group is significantly smaller than that that of the low EPO level group in patients with AMI subjected to successful primary PCI. There is a negative correlation between the two groups.
出处 《心脏杂志》 CAS 2008年第5期608-609,615,共3页 Chinese Heart Journal
关键词 心肌梗死 急性 直接经皮冠状动咏介入治疗 梗死面积 促红细胞生成素 myocardial infarction, acute primary percutaneous coronary intervention infarct size erythropoietin
  • 相关文献

参考文献7

  • 1Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling [ J ]. Proc Natl Acad Sci USA, 2003, 100 ( 8 ) :4802 - 4806.
  • 2Cai Z, Manalo DJ, Wei G, et al. Hearts from redents exposed to intermittent hypoxia or erythropoietin are protected against ischemiareperfusion injure [ J ]. Circulation, 2003, 108 ( 1 ) :79 - 85.
  • 3Sobel BE, Bresnahan GF, Shell WE, et al. Estimation of infarction size in man and its relation on prognosis[ J ]. Circulation, 1972, 46 ( 4 ) :640 - 648.
  • 4Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance [ J ]. Ann Hematol, 1994, 68 ( 5 ) :215 - 223.
  • 5Tanabe N, Ohnishi K, Fukui H, et al. Effect of smoking on the serum concentratin of erythropoietin and granulocyte-clolony stimulating factor[J]. Intern Med, 1997, 36(10) :680 -684.
  • 6Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro [ J ]. Cardiovasc Drugs Ther, 2005, 19(5) :333 -336.
  • 7Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization [J]. Blood, 2003, 102(4) :1340 - 1346.

同被引文献13

  • 1Ruifrok W P, Lipsic E, de Boer R A, et al. Erythropoiesis stimulation in acute ischemic syndromes [J]. Heart Fail Clin, 2010,6(3) :313-321.
  • 2Namiuchi S, Kagaya Y, Ohta J, el al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary pereutaneous coronary intervention [J]. J Am Coil Cardiol, 2005,45(9) : 1406-1412.
  • 3Ghaboura N, Tamareille S, Ducluzeau P H, el al. Diabetes mellitus abrogates erythropoietin-induced eardioprotection against ischemic-reperfusion injury by aheration of' the RISK/ GSK-313 signaling [J]. Basic Res Cardiol, 2011,106( 1 ) : 147- 162.
  • 4Suh J W, Chung W Y, Kim Y S, et al. The effecl of intravenous administration of et'ythropoietin on the infarct size in primary percutaneous coronary intervention [J]. Int J Cardiol, 2011, 149(2) :216-220.
  • 5bhen Y, Wang Y, l,i D, et al. Itecombinant human erythropoietin pretreatment attenuates heart isehemia-reperfusion injury in rats by suppressing the systemic inflammatot3' response [J]. Transplant Proe, 2010,42(5) : 1595-1597.
  • 6Ruifrok W P, Lipsic E, de Boer R A, et al. Erythropoiesis stimulation in acute ischemic syndromes [J]. Heart Fail Clin, 2010,6(3):313-321.
  • 7Vander Merr P, Voors A A, Lipsic E, et al. Erythropoielin in cardiovascular diseases [J ]. Eur Heart J, 2004,25 (4) : 285- 291.
  • 8Santhanam A V, d'Uscio L V, Katusic Z S. Cardiovascular effects of erythropoietin an update [J]. Adv Pharmaeol, 2010, 60 : 257-285.
  • 9Kaneda T, Tsuruoka S, Fujimura A. Statins inhibited erythropoietin-induced proliferation of rat vascular smoolh muscle cells [ J]. Eur J Pharmacol, 2010, 649 ( 1 - 3 ) : 38-43.
  • 10Yang B, Hosgood S A, Bagul A, et al. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-lβin isolated hemoperfused kidneys [J]. Eur J Pharmacol, 20 l 1,660 ( 2-3 ) : 420-430.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部